PTIX Protagenic Therapeutics Inc.: Enterprise Value to EBITDA Ratio
The market value of Protagenic Therapeutics (PTIX) on the GURU.Markets platform, which stands at 0.00 as illustrated on this chart, underscores the significance of peptide patents and massive R&D investments that create barriers to entry under strict FDA oversight. Protagenic Therapeutics (PTIX) focuses on developing innovative antidepressants leveraging its proprietary technological platform. Current success is based on progressing through clinical stages and maintaining strict operational expense management while retaining sufficient liquidity.
PTIX (protagenic.com): analytical breakdowns and indicator data
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
Total Debt to Capital Protagenic Therapeutics|PTIX - Long-Term Liabilities to Capital|Short-Term Debt to Equity Protagenic Therapeutics, Inc.|PTIX - Company Aggregate Debt|Debts to Book Capitalization Protagenic Therapeutics, Inc.|PTIX - Long-Term Debt Volume|Company Short-Term Debts Protagenic Therapeutics|Quick Liquidity Indicator protagenic.com
- financial results and valuation multiples details:
PTIX - Final Profit|Future Profit Protagenic Therapeutics|PTIX - Market Price to Net Income Ratio|Forward P/E Multiple Protagenic Therapeutics, Inc.|PTIX - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Protagenic Therapeutics, Inc.|PTIX - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Protagenic Therapeutics|PTIX - Earnings per share for the trailing year|Quarterly EPS earnings growth protagenic.com|PTIX - Earnings growth in current year|Net earnings per share growth forecast for next year Protagenic Therapeutics
Fundamental company valuation:Protagenic PTIX
This ratio compares the total enterprise value, including net debt, to operating profit before depreciation and amortization, determining the payback period for assets. For Protagenic Therapeutics (PTIX), this metric reflects the investment efficiency of robotic protein analysis platforms relative to the generated cash flow. By analyzing the historical EV/EBITDA trend of the company, an investor can assess market expectations regarding drug development rates and the stability of the capital structure.
Analysis of competing companies
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biogen Corp BIIB|Neurocrine Corp (NBIX) - Company Value to EBITDA|RGC: Enterprise Value to EBITDA Ratio|axsome.com - Enterprise Value to Operating Income Before Depreciation Ratio|ACAD: EV/EBITDA Multiple|Xenon Pharmaceuticals Inc. (XENE) - EV/EBITDA Multiple|VKTX (Viking Pharma) - EV/EBITDA Multiple|SUPN - Enterprise Value to EBITDA Multiple|EV/EBITDA Multiple CPRX|DNLI - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harmony Biosciences Holdings, Inc. HRMY|BHVN: Enterprise Value to Operating Income Before Depreciation|Amylyx - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Trevi Corp TRVI|PRAX: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio anavex.com|Enterprise Value to EBITDA Ratio CBLL|PRTA: Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio ALEC (Alector, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio ANNX|EV/EBITDA Multiple OMER (Omeros)|Business Value to Operating Income Before Depreciation NGNE|AC Immune SA - EV/EBITDA Multiple|Company Value to EBITDA Voyager Therapeutics Inc|Neumora Therapeutics Inc (NMRA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Scilex Holding Company, Inc. - Business Value to Operating Income Before Depreciation|TVGN (Tevogen Bio Holdings) - EV/EBITDA Multiple|EV/EBITDA Multiple Alpha Cognition Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cognition Therapeutics, Inc. (CGTX)|IKT: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple SAVA (Cassava)|Assertio Holdings (ASRT) - Company Value to EBITDA|COYA: Enterprise Value to EBITDA Ratio|VTGN - EV/EBITDA Multiple|OVID (ovidrx.com) - Enterprise Value to EBITDA Ratio|ABOS: Enterprise Value to Operating Income Before Depreciation Ratio|CRVO (CervoMed Inc) - EV/EBITDA Multiple|Alterity Therapeutics Ltd (ATHE) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple CLNN|Enterprise Value to EBITDA Ratio pepgen.com PEPG|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Jupiter Neurosciences JUNS|Total Company Value to Operating Income Before Depreciation Ratio Relmada Therapeutics Inc (RLMD)|ANVS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio GRCE|AIFF (Firefly Neuroscience, Inc) - Enterprise Value to EBITDA Ratio|KLTO: Enterprise Value to Operating Income Before Depreciation Ratio|NRSN (NeuroSense Therapeutics Ltd) - EV/EBITDA Multiple|Reviva Pharmaceuticals Holdings Inc. (RVPH) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio MTVA (MetaVia Inc)|NeurAxis Inc - Enterprise Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Helius Medical Technologies HSDT|PASG: Enterprise Value to Operating Income Before Depreciation|Neuphoria - EV/EBITDA Multiple|Company Value to EBITDA Minerva Neurosciences Inc|ATHA (Athira) - Enterprise Value to EBITDA Ratio|Addex (ADXN) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alzamend Neuro Inc.|CYCN: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pasithea Therapeutics (KTTA)|CRGT - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Avenue Therapeutics, Inc ATXI|BCLI (BrainStorm Cell Therapeutics Inc.) - Company Value to Operating Income Before Depreciation Ratio|CARA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation CHRO (chromocell.com)|eliemtx.com (ELYM) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Intra-Cellular Therapies, Inc. (ITCI)|Enterprise Value to EBITDA Ratio LBPH|MRNS (Marinus Pharma) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple NKGN|EV/EBITDA Multiple neurobopharma.com (NRBO)|EV/EBITDA Multiple SAGE (Sage Therapeutics)|Enterprise Value to EBITDA Multiple Synaptogenix Inc.|Trevena, Inc - EV/EBITDA Multiple|Company Value to EBITDA Vigil Neuroscience|Anew Medical, Inc. (WENA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation CERE
